Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 2,701–2,800 of 3,636
Baessler, A., & Fischer, M. (2022) · Herz · doi:10.1007/s00059-022-05111-z · Cited by 2
Guijarro, C., Civeira, F., López‐Miranda, J., et al. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.01.002 · Cited by 1
Schäfer, J., & Vogelmeier, C. F. (2019) · Der Internist · doi:10.1007/s00108-019-0582-y · Cited by 1
Management of hyperlipidaemia following acute coronary syndrome: a retrospective audit
Salim, H., Lwin, K., Khoo, C. W., & Wilson, D. G. (2021) · British Journal of Cardiology · doi:10.5837/bjc.2021.017 · Cited by 2
Mal, G. S., & Kuznetsov, A. A. (2022) · Innovative medicine of Kuban · doi:10.35401/2541-9897-2022-25-2-14-21 · Cited by 3
Kuznetsov, A. A., & Mal, G. S. (2022) · Regional blood circulation and microcirculation · doi:10.24884/1682-6655-2022-21-2-16-25 · Cited by 1
PCSK9 inhibitors and treatment targets: an audit-based evaluation of a specialist lipid clinic
Suresh, A., Theodoraki, A., Ward, E., & Feher, M. D. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.342 · Cited by 3
RNA modification by M6A methylation in cardiovascular diseases: Current trends and future directions
Wang, J., & Zha, L. (2022) · Frigid Zone Medicine · doi:10.2478/fzm-2022-0023 · Cited by 1
Pedro‐Botet, J., Barrios, V., Sánchez‐Margalet, V., Tamargo, J. L., Arrieta, F., Gámez, J. M., Gimeno-Orna, J. A., Escobar, C., Gómez‐Doblas, J. J., & Pérez, A. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.11.009 · Cited by 2
2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea
Lee, C. J., Yoon, M., Kang, H., Kim, B. J., Choi, S. H., Jeong, I., Lee, S., & on behalf of Task Force Team for Familial Hypercholesterolemia, K. S. O. L. A. A. (2022) · Korean Journal of Medicine · doi:10.3904/kjm.2022.97.6.339 · Cited by 1
Early initiation of PCSK9 inhibition in myocardial infarction could be EPIC for patient care
Bhatt, D. L. (2022) · EuroIntervention · doi:10.4244/eij-e-22-00047 · Cited by 1
Self-citationМухортова, П. А., Bessonova, T. O., Терян, Р. А., Shemyakova, O. S., Matrenin, К. I., Bagdasarov, A., & Musina, N. Z. (2022) · Medical Technologies Assessment and Choice · doi:10.17116/medtech20224404151 · Cited by 1
Efficacy and safety of the use of alirocumab in real clinical practice
Korneva, V. A., Kuznetsova, Т. Y., Scopets, I. S., & Vezikova, N. N. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.12.201991 · Cited by 2
Kim, J. Y., & Kim, N. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0454 · Cited by 1
“A linear relationship between low-density lipoprotein cholesterol (LDL-C) level and incident CVD has been observed in patients with DM, as well as in individuals without DM [2,3].”
InfluentialRabih, A. M., Niaj, A., Raman, A., Uprety, M., Calero, M. J., Villanueva, M. R. B., Joshaghani, N., Villa, N., Badla, O., Goit, R., et al. (2023) · Cureus · doi:10.7759/cureus.34648 · Cited by 2
Bashir, B., Iqbal, Z., Schofield, J. D., & Soran, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00012-7 · Cited by 1
Manyari, D. E., Belenkie, I., & Quiroz, O. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-17650-0_31 · Cited by 4
Lipid modification in people with diabetes
Morris, D. (2023) · Prescriber · doi:10.1002/psb.2053 · Cited by 1
Abordagens terapêuticas nas dislipidemias - com ênfase na ldl-c (aterogênica)
Guerra, T. D. R. B., Soares, A. D. C. L., Salviano, B. M., Palermo, M. V. A., Scofano, B. D. S., Netto, M. F. G., Nunes, B. E. M., & Tavares, A. P. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n2-288 · Cited by 2
New approaches to reduce recurrent PCI: to angioplasty and beyond!
Sabouret, P. F., Manzo‐Silberman, S., Alasnag, M. A., Fysekidis, M., Gulati, M., Galati, G., Spadafora, L., Banach, M., Biondi‐Zoccai, G., & Bhatt, D. L. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead049 · Cited by 2
“8 years.(30) In patients with LDL-C levels of 70 mg/dL or higher on maximal tolerated dose of statin therapy, both trials demonstrated that PCSK9i reduced the primary combined endpoint (MI, stroke, cardiovascular death, hospitalisation, unstable angina, or coronary revascularisation) with a relative risk reduction of…”
InfluentialSelf-citationApplication Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis
Zhao, L., Liu, Y., Cao, Z., Wang, J., & Huo, X. (2023) · Iranian Journal of Public Health · doi:10.18502/ijph.v52i5.12707 · Cited by 1
PCSK9-hemmere på blå resept for hvem?
Semb, A. G., Vesterbekkmo, E. K., Retterstøl, K., Atar, D., Solberg, E. E., Schirmer, H., Løchen, M., Kask, A., Grimsmo, J., Ingul, C. B., et al. (2023) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.23.0191 · Cited by 2
Genetics of Coronary Artery Disease in Diabetes Mellitus
Morieri, M. L., & Doria, A. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_6 · Cited by 1
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
Modern prospects of targeted hypolipidemic therapy
Kuchmin, A. N., Борисович, Н. М., Grachev, A. M., & Смирнова, Е. В. (2023) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma321350 · Cited by 1
Lipoprotein(a): Solving the Puzzle, Deciphering the Riddle, Unraveling the Enigma
Thanassoulis, G. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.018 · Cited by 1
Nonproportional Hazards Demystified: Why They Matter for Planning and Interpreting Clinical Trials
Gregson, J., & Pocock, S. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.08.008 · Cited by 1
Likozar, A. R., & Šebeštjen, M. (2023) · Cardiovascular Ultrasound · doi:10.1186/s12947-023-00313-9 · Cited by 1
Heart crosstalk with other organs and pharmacological strategies for cardioprotection
Tu, Z., & Xiang, Y. (2022) · Journal of Holistic Integrative Pharmacy · doi:10.1016/s2707-3688(23)00062-6 · Cited by 1
wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
Ilnicka, N., Zuziak, P., Sadlik, M., Matyja, D., & Abod, L. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.15.01.014 · Cited by 1
Lipidmanagement zur Reduktion des kardiovaskulären Risikos bei Typ-2-Diabetes
Brandts, J. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01094-5 · Cited by 1
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
Shnaider, K. O., Maksimov, М. L., Baranova, V. A., & Nekipelova, A. A. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-366 · Cited by 1
PCSK9 in extrahepatic tissues: What can we expect from its inhibition?
Pirillo, A., Tokgözoğlu, L. S., & Catapano, A. L. (2023) · European Atherosclerosis Journal · doi:10.56095/eaj.v2i2.47 · Cited by 2
“Short-term clinical trials with mAbs targeting PCSK9 found no association between very low LDL-C levels and cognitive impairment (13, 25-29).”
Ponir, C., Seals, A. L., Caldarera, T., Ip, E. H., German, C. A., Taylor, Y. J., Moore, J. B., Bosworth, H. B., Shapiro, M. D., & Pokharel, Y. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad082 · Cited by 1
Caldarera, T., Ponir, C., Seals, A. L., Penmetsa, M., Ip, E. H., German, C. A., Virani, S. S., Saha, A., Bosworth, H. B., Moore, J. B., et al. (2023) · Future Cardiology · doi:10.2217/fca-2023-0040 · Cited by 1
Consideraciones clínicas y estrategias terapéuticas para reducir el riesgo residual
Olmo, M. R. F., & Llergo, J. T. (2023) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(23)00011-0 · Cited by 2
¿Qué es el riesgo cardiovascular residual? Etiología, lípidos e inflamación
Badimón, L., Vilahur, G., Padró, T., & Mendieta, G. (2023) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(23)00008-0 · Cited by 2
Dyslipoproteinaemia: Important Concern in Type 2 Diabetes
Kumwenda, M. J. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002514 · Cited by 1
Lawler, P. R., Manvelian, G. Z., Coppi, A., Damask, A., Cantor, M. N., Ferreira, M. A. R., Paulding, C., Banerjee, N., Li, D., Jorgensen, S., et al. (2023) · Critical Care Explorations · doi:10.1097/cce.0000000000000997 · Cited by 1
Self-citationEfficacy and tolerability of PCSK9 inhibitors in real-world clinical practice
Devaiah, P., Handjiev, S., & George, J. (2023) · British Journal of Cardiology · doi:10.5837/bjc.2023.044 · Cited by 4
Confluence of Mendelian Randomization with Clinical Trials as To Very Low Levels of LDL Cholesterol
Chacra, A. P. M., Saldanha, A. L. R., Margeotto, A. P. P., Gasparoto, A. L. V., Ampuero, M. S. S., Castro, L. F. D., & Martinez, T. L. D. R. (2024) · Clinical Medicine And Health Research Journal · doi:10.18535/cmhrj.v4i1.304 · Cited by 1
“The treatment group achieved mean LDL-C levels of 53.3 mg/dl and the group 101.4 mg/dl with a drop of 54.7mg/dl and reductions in combined outcomes including death from CAD of 15% [19].”
BackgroundInfluentialEffect of statin add-on therapy on cardiovascular mortality
Nelson, J. R., Le, V. T., Anderson, J. L., & Ciffone, N. A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1308695 · Cited by 1
“No P value was reported for this CV mortality endpoint because hierarchical analysis was stopped after the fi rst nonsigni fi cant P value was observed for death from coronary heart disease ( P = 0.38) (15).”
BackgroundInfluentialOS TIPOS DE TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA E CONTROLE DOS TRIGLICERÍDEOS
Nogueira, D. R., Melo, G. C. D. C., Silva, I. D. A. C. E., Moreira, L. E. P., Pedrosa, M. D. S. B., Cardinali, M. D. P., Peron, P. L. V., & Piazzi, R. G. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p13 · Cited by 4
Tada, H., Kojima, N., Kawashiri, M., & Takamura, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29924 · Cited by 1
“It is interesting to note that these observations in extreme human-knockout are in line with the findings obtained in clinical trials using APOB inhibitor and PCSK9 inhibitor [4,5].”
ResultProspects of Using PCSK9 Inhibitors for Acute Coronary Syndrome
Муратович, Н. А., Зафираки, В. К., & Витальевна, К. К. (2024) · Innovative medicine of Kuban · doi:10.35401/2541-9897-2024-9-2-124-128 · Cited by 1
Cholesterol, Atherosclerosis, Lipid-Lowering Therapy. Is It Completely Clear?
Vasiliev, A. P., & Streltsova, N. N. (2024) · Ural Medical Journal · doi:10.52420/umj.23.2.131 · Cited by 1
Kim, N., Cho, J., & Yang, I. (2024) · Biomedicines · doi:10.3390/biomedicines12051113 · Cited by 1
Nong, J., You, W., Wang, Y., Xu, Y., Xu, T., Meng, P.-N., Wu, X., Wu, Z., Kong, X.-H., Jia, H., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302547 · Cited by 1
Pharmacotherapies for Cardiovascular Disease Prevention
Ballard‐Hernandez, J., & Irwin, C. W. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_14 · Cited by 1
Zhang, N. (2024) · American Journal of Translational Research · doi:10.62347/kifr7353 · Cited by 1
Xu, L., Wang, Y., Wang, Y., Wang, L., Du, P., Cheng, J. L., Zhang, C., Jiao, T., Xing, L., Tapu, M. S. R., et al. (2024) · Pharmacology · doi:10.1159/000540083 · Cited by 3
“Primary conclusions from the ODYSSEY OUT-COMES and FURIER studies indicated that PCSK9i has the potential to reduce long-term cardiovascular events [17, 18].”
Hibi, K., Gohbara, M., Uemura, K., Iwahashi, N., Okada, K., Iwata, H., Fukumoto, Y., Hiro, T., Ozaki, Y., Iimuro, S., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.07.002 · Cited by 1
Design of the “EAST” strategy in patients with asymptomatic intracranial atherosclerotic stenosis
Chen, X., Dai, J., Nie, P., et al. (2024) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2024.108507 · Cited by 1
Sallam, M., Hassan, H., Connolly, D. L., & Rahman, M. S. (2024) · European Cardiology Review · doi:10.15420/ecr.2024.06 · Cited by 2
Lehrke, M., Mueller, S., Maywald, U., Deiters, B., Fraass, U., & Stein, A. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2433379 · Cited by 1
Top 10 Tips for Using Statins in Clinical Practice
Rangwani, S. M., Maning, J., & Stone, N. J. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.025 · Cited by 1
Sciahbasi, A., Russo, P., Zuccanti, M., Chiorazzo, L., Castelli, F., & Granatelli, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237420 · Cited by 1
“…with Elevated Risk (FOURIER) trial [50] and in the Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (ODYSSEY OUTCOMES) trials [51].”
10.1016/b978-0-323-63600-1.00005-3
(2000) · Time to knit · doi:10.1016/b978-0-323-63600-1.00005-3 · Cited by 1
Gavina, C., Carvalho, D. S., Afonso-Silva, M., Costa, I., Freitas, A. S., Canelas‐Pais, M., Lourenço‐Silva, N., Taveira‐Gomes, T., & Araújo, F. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200385 · Cited by 2
“The ODYSSEY Outcomes trial provided evidence that alirocumab, another PCSK9 inhibitor, significantly reduced the risk of recurrent CV events in post-ACS patients with elevated LDL-C levels despite statin therapy, offering an alternative for patients who require further LDL-C lowering [17].”
Early effects of PCSK9 inhibitors: evolocumab versus alirocumab
Bae, S. H., Kim, B., Kim, S. J., et al. (2025) · Kosin Medical Journal · doi:10.7180/kmj.24.145 · Cited by 1
Chow, C. K., Archer, O., & Kritharides, L. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.453 · Cited by 1
Reducing the risk of heart attack: the key role of lipid profiling and atherosclerosis imaging
Biccirè, F. G., Mastroianni, F., Celeski, M., Gatto, L., & Prati, F. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf010 · Cited by 1
Li, L., Sun, H., Jin, Z., Li, J., Fang, Y., Zuo, L., Sun, P., Li, Y., Richards, M., Foo, R., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.04.021 · Cited by 1
Sobhy, M. A., Badran, H. M., Hassanein, M., Rafla, S. M., Zawawy, T. E., Zaki, A. M., Loutfi, M. I., Sadaka, M. A., Ayad, S. W., Kamal, A., et al. (2025) · The Egyptian Heart Journal · doi:10.1186/s43044-025-00655-x · Cited by 3
Pedro‐Botet, J., Freixa‐Pamias, R., Tamarit, J. J., López‐Miranda, J., Fernández-Olmo, R., Muñiz-Grijalvo, O., Vázquez, R., Guijarro, C., Padial, L. R., Díaz-Díaz, J. L., et al. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100738 · Cited by 2
Razavi, A. C., Sokolsky, M., & Blumenthal, R. S. (2025) · Archives of Medical Science · doi:10.5114/aoms/207067 · Cited by 2
“…3 CVD outcome trials demonstrating utility of combination lipid lowering therapy when added to statins for ezetimibe (IMPROVE-IT, 2015) [7] and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (FOURIER [8] & ODYSSEY OUTCOMES [9], 2017–2018) were completed 8–10 years ago.”
Mostaza, J. M., Lahoz, C., Castro, M. G. D. Y., Campal, J. M. R., Velásquez, E., Gutiérrez, A. I., Díaz, J. F., Plana, N., Rodríguez‐Mañero, M., García-Díaz, J. D. D., et al. (2025) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2025.502344 · Cited by 3
Galli, L., Bernhard, J., Schrutka, L., Haider, P., Distelmaier, K., Hengstenberg, C., Krychtiuk, K. A., & Speidl, W. S. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02716-2 · Cited by 1
“…outcome trials on the possibility and the benefits of achieving very low levels of LDL-C with virtually no lower limit described [7, 9, 16, 17], the 2019 ESC/EAS guidelines for dyslipidemia management introduced an ambitious LDL-C target goal of 55 mg/dL for very high-risk patients.”
Zhang, L., Li, Y.-Y., Liu, X.-H., Liu, H.-J., & Xu, Q. (2025) · PLOS One · doi:10.1371/journal.pone.0329676 · Cited by 1
“Among these, two trials [19,26] evaluated alirocumab, two trials [13] evaluated bococizumab, and one trial [25] evaluated evolocumab.”
InfluentialHow to reach optimal cardiovascular risk profile in carotid artery stenosis
Pitha, J. V. (2025) · International Angiology · doi:10.23736/s0392-9590.25.05442-2 · Cited by 1
Bhatia, R., Dhawan, V., Bhatia, A., Gupta, R., & Gupta, M. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_50_2025 · Cited by 2
Targeting PCSK9 to reduce residual risk in ACS
Fernández-Ruíz, I. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0125-6 · Cited by 1
Peterson, E. D., & Greenland, P. (2019) · JAMA · doi:10.1001/jama.2019.0045 · Cited by 1
Ruiz, S. P., Parra‐Virto, A., do Rego, A. T., Rodríguez, P. D., & Álvarez-Sala, J. L. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.04.003 · Cited by 1
PCSK9 Function and Cardiovascular Death
Schwartz, G. G., & Taylor, M. R. G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.518 · Cited by 1
Self-citationАхмеджанов, Н. М., Vezikova, N. N., Voevoda, M. I., Galyavich, A. S., Gurevich, V. S., Duplyakov, D. V., Владиславович, Е. М., IuA, K., Кашталап, В. В., Konovalov, G. A., et al. (2019) · Kardiologiia · doi:10.18087/cardio.n308 · Cited by 1
Three-year events and mortality in cardiovascular disease patients without lipid-lowering treatment
Degano, I. R., Ramos, R., García-Gil, M., Zamora, A., Comas‐Cufí, M., Francés, A., García-Elías, A., & Marrugat, J. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319862103 · Cited by 1
Pharmacoeconomic rationale for alirocumab administration in acute coronary syndrome
Nedogoda, S. V., Chumachek, E. V., & Salasyuk, A. S. (2019) · Clinical pharmacology and therapy · doi:10.32756/0869-5490-2019-2-99-104 · Cited by 1
Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
Παναγιωτοπούλου, Ό., Chiesa, S. T., Tousoulis, D. M., & Charakida, M. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190827151012 · Cited by 1
Kostapanos, M. S., Cacciottolo, P. J., Hubsch, A., Pavey, H., Hurlock, J., Maki-Petaja, K. M., Wilkinson, I. B., & Cheriyan, J. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1677673 · Cited by 1
Effects of a short-term alirocumab administration on the aortic stiffness: preliminary results.
Mauro, F., Ferreri, C., Rossi, A., Marzia, T., Gaetano, R., & Tassone, F. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.10.001 · Cited by 2
Behandlungsoptionen bei schweren Hypercholesterinämien
Vogt, A. (2019) · CardioVasc · doi:10.1007/s15027-019-1672-4 · Cited by 1
“Die Endpunktstudien bestätigen, dass der klinische E¢ekt umso besser ist, je weiter LDL-C gesenkt wird [16, 17].”
BackgroundManejo de la intolerancia a estatinas: un desafío cotidiano en la práctica clínica
Miranda, N. (2019) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.34.3.25 · Cited by 3
“Hasta el momento dos grandes estudios avalan el beneficio en eventos cardiovasculares: ODYSSEY con alirocumab (Praluent)(13) y FOURIER con evolocumab (Repatha)(14), como se profundizará en el artículo específico referido a estos fármacos.”
BackgroundMancini, G. B. J., Bergeron, J., FITCHETT, D. H., Genest, J. J., Gupta, M., Hegele, R. A., Ng, D. S., Pearson, G. J., & Pope, J. E. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-33304-1_16 · Cited by 1
‘Fishing’ for therapies to ‘net’ cost-effective benefits
Milks, M. W. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320913812 · Cited by 1
PCSK9 inhibitors: Going forward and beyond
Attar, A. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320916964 · Cited by 1
Buckley, L. F., Ting, C., Fatani, N., & Fanikos, J. R. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.04.003 · Cited by 1
Recent Guideline for the Management of Dyslipidemia in Patients with Diabetes
Rhee, E. (2020) · Journal of Korean Diabetes · doi:10.4093/jkd.2020.21.1.11 · Cited by 1
Low cholesterol syndrome and drug development
Handhle, A., Viljoen, A., Ramachandran, R., & Wierzbicki, A. S. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000745 · Cited by 3
“Both human monoclonals lower LDL-C by 45–55% and also reduce CVD events in outcomes trials [21,22].”
BackgroundWerdan, K., Müller‐Werdan, U., & Perings, S. M. (2020) · Aktuelle Kardiologie · doi:10.1055/a-1179-5728 · Cited by 1
Begründung für die neuen LDL-Cholesterin-Zielwerte
Otto, S., Schulze, P. C., & Weingärtner, O. (2020) · Aktuelle Kardiologie · doi:10.1055/a-1200-1322 · Cited by 1
Inhibidores de la PCSK9: una nueva era en el control del riesgo cardiovascular
Miranda, N. (2019) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.34.3.26 · Cited by 1
PCSK9 Inhibition and Atherosclerosis: Current Therapeutic Option and Prospection
Pandey, P., Zhao, C., & Liu, B. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0904-0_12 · Cited by 1
Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease
Mahajan, K., & Chandra, K. S. (2020) · Indian Journal of Clinical Cardiology · doi:10.1177/2632463620943020 · Cited by 1
Hypercholesterinämie - Wie erreiche ich ein LDL < 55 mg/dl?
Vogt, A. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-4373-0 · Cited by 1
Tuñón, J., Lázaro, A. M. P., López‐Castillo, M., & Aceñaa, Á. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30025-x · Cited by 1
Benefits of LDL cholesterol reduction in the secondary prevention of ischemic stroke New evidence
Armario, P., & Jericó, C. R. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2020.12.001 · Cited by 1
It's never too early to beat your low-density lipoprotein cholesterol
Bergerot, C., Angoulvant, D., Lemesle, G., et al. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.01.001 · Cited by 1
Iodine in Table Salt in the Aseer Region, Southwestern Saudi Arabia
Patel, A. A. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.93977 · Cited by 1
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

